Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2318965 | 0.98 | HDAC4 (0.42) | SLC6A4SLC6A3HSD11B1SLC6A2HDAC4 | |
| SCHEMBL1795 | 0.94 | HSD11B1 (0.39) | SLC6A4SLC6A3HSD11B1SLC6A2HDAC4 | |
| SCHEMBL75311 | 0.90 | HSD17B10 (0.38) | SLC6A4SLC6A3HSD11B1HDAC4 | |
| SCHEMBL1807152 | 0.81 | SLC6A3 (0.44) | SLC6A4SLC6A3HSD11B1SLC6A2 | |
| SCHEMBL2861574 | 0.81 | DRD3 (0.45) | SLC6A4SLC6A3SLC6A2HDAC4 | |
| SCHEMBL4678558 | 0.79 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL5276713 | 0.79 | SLC6A3 (0.42) | SLC6A4SLC6A3HSD11B1SLC6A2 | |
| SCHEMBL6792552 | 0.79 | SLC6A4 (0.49) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4735252 | 0.79 | DRD3 (0.46) | SLC6A4SLC6A3SLC6A2HDAC4 | |
| SCHEMBL4145354 | 0.76 | SLC6A4 (0.46) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2421826-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | SLC6A4 985/4885SLC6A3 1543/4885HSD11B1 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.